| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2006 | EP1654000A1 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
| 05/10/2006 | EP1653997A1 Methods and compositions for controlling ectoparasites |
| 05/10/2006 | EP1653993A1 Use of chemokines, and pharmaceutical preparations containing the same |
| 05/10/2006 | EP1653989A2 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
| 05/10/2006 | EP1653986A2 Treatment of cancers expressing p95 erbb2 |
| 05/10/2006 | EP1653984A2 Drug delivery systems for tumor targeting by ngr-molecules and uses thereof |
| 05/10/2006 | EP1653983A1 Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil |
| 05/10/2006 | EP1653980A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 05/10/2006 | EP1653977A2 Treatment of disorders associated with natural killer t cells |
| 05/10/2006 | EP1653976A1 Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
| 05/10/2006 | EP1653975A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| 05/10/2006 | EP1653974A1 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application |
| 05/10/2006 | EP1653972A1 Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
| 05/10/2006 | EP1653971A2 Treatment of sleep disorders with cholinesterase inhibitors |
| 05/10/2006 | EP1653970A2 Gsk-3 inhibitors and uses thereof |
| 05/10/2006 | EP1653969A2 Pyrrolo 1,2-b pyridazine derivatives |
| 05/10/2006 | EP1653968A2 Method for modulating calcium ion-release-activated calcium ion channels |
| 05/10/2006 | EP1653967A2 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
| 05/10/2006 | EP1653966A1 Treatment of sexual dysfunction |
| 05/10/2006 | EP1653964A1 Cancer combination therapy comprising azd2171 and zd1839 |
| 05/10/2006 | EP1653963A1 Nasal pharmaceutical composition of piribedil |
| 05/10/2006 | EP1653962A2 Pyrazine modulators of cannabinoid receptors |
| 05/10/2006 | EP1653961A1 Inhibitors of akt activity |
| 05/10/2006 | EP1653960A2 Melanin concentrating hormone receptor antagonist |
| 05/10/2006 | EP1653959A2 Lipid-modified immune response modifiers |
| 05/10/2006 | EP1653958A1 Nicotinamide compounds useful as pde4 inhibitors |
| 05/10/2006 | EP1653957A1 Piperidine compounds useful as malonyl-coa decarboxylase inhibitors |
| 05/10/2006 | EP1653956A1 Combinations of paroxetine and 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid ¬1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl|methylamide for treatment of depression and/or anxiety. |
| 05/10/2006 | EP1653955A2 Hydroxylamine substituted imidazo-containing compounds |
| 05/10/2006 | EP1653954A1 Antibiotic thiazolidines |
| 05/10/2006 | EP1653953A2 Drug delivery methods and devices |
| 05/10/2006 | EP1653952A2 Oxazole compounds for the treatment of neurodegenerative disorders |
| 05/10/2006 | EP1653949A2 Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 05/10/2006 | EP1653948A2 Use of 5-methoxytryptamine as a cardioprotective agent |
| 05/10/2006 | EP1653946A2 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors |
| 05/10/2006 | EP1653945A2 Glycosidase inhibitors and methods of synthesizing same |
| 05/10/2006 | EP1653944A1 Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
| 05/10/2006 | EP1653943A2 Compounds and methods for inducing apoptosis in cancer cells |
| 05/10/2006 | EP1653942A1 Methods of therapeutic treatment using amounts of retinoid components |
| 05/10/2006 | EP1653941A1 Methods of therapeutic treatment using amounts of retinoid components |
| 05/10/2006 | EP1653940A1 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor |
| 05/10/2006 | EP1653939A2 Method for treating cachexia with retinoid ligands |
| 05/10/2006 | EP1653938A2 Methods of treatment of inflammatory bowel disease with lxr agonists |
| 05/10/2006 | EP1653937A1 Compounds useful for treating neurological disorders |
| 05/10/2006 | EP1653936A2 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 05/10/2006 | EP1653935A1 Anti-inflammatory formulations |
| 05/10/2006 | EP1653934A2 Use of c-kit inhibitors for treating type ii diabetes |
| 05/10/2006 | EP1653933A1 Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil |
| 05/10/2006 | EP1653932A1 Modified release compositions for minocycline |
| 05/10/2006 | EP1653930A2 Methods for the stabilization of atorvastatin |
| 05/10/2006 | EP1653929A1 Solid pharmaceutical composition comprising ramipril |
| 05/10/2006 | EP1653928A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 05/10/2006 | EP1653926A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 05/10/2006 | EP1653922A2 Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
| 05/10/2006 | EP1653914A2 Oxime substituted imidazo-containing compounds |
| 05/10/2006 | EP1653911A2 Methods for treating metabolic syndrome |
| 05/10/2006 | EP1653910A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 05/10/2006 | EP1653895A1 Condom with a coating and composition |
| 05/10/2006 | EP1653815A1 Methods for reducing astringency |
| 05/10/2006 | EP1653814A1 Plant sterol-containing food, and method for preparing the same |
| 05/10/2006 | EP1624899A4 Increased transduction using abc transporter substrates and/or inhibitors |
| 05/10/2006 | EP1560812B1 Aminocyclohexyl ether compounds and uses thereof |
| 05/10/2006 | EP1536799B1 Novel 2-amino-4-oxoquinazolones as lxr nuclear receptor binding compounds with partial agonistic properties |
| 05/10/2006 | EP1509598A4 Induction of insulin expression |
| 05/10/2006 | EP1497290A4 Process for preparing acid salts of gemifloxacin |
| 05/10/2006 | EP1495006A4 Inhibitors of glycinamide ribonucleotide transformylase |
| 05/10/2006 | EP1483374B1 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vitro |
| 05/10/2006 | EP1478329B1 Orally administrable composition for the photoprotection of the skin |
| 05/10/2006 | EP1418911B1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| 05/10/2006 | EP1414832B1 Gold compounds simultaneously coordinated by mono- and bidentate phosphines having antitumoral activity |
| 05/10/2006 | EP1412354B1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 05/10/2006 | EP1411765A4 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 05/10/2006 | EP1370553B1 Rho-kinase inhibitors |
| 05/10/2006 | EP1307189B1 Use of hydroxyethylrutosides for treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 05/10/2006 | EP1294874B1 Cd154 variants and uses thereof |
| 05/10/2006 | EP1284738A4 (+) naloxone and epinephrine combination therapy |
| 05/10/2006 | EP1265838B9 Novel fatty acid analogous |
| 05/10/2006 | EP1255764B1 Purine derivatives |
| 05/10/2006 | EP1224205B1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 05/10/2006 | EP1219605B1 Urea compounds, process for producing the same and use thereof |
| 05/10/2006 | EP1212296B9 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 05/10/2006 | EP1210355B1 Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof |
| 05/10/2006 | EP1140786B9 Reductive alkylation of secondary amines with hydrosilane |
| 05/10/2006 | EP1137948B1 Methods and compositions to lower plasma cholesterol levels |
| 05/10/2006 | EP1104403B1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 05/10/2006 | EP1049700B9 Chemokine receptor antagonists and methods of use therefor |
| 05/10/2006 | EP1047423B1 Novel apoptosis inhibitors |
| 05/10/2006 | EP1016407B1 Xanthine derivatives for treating brain ischemia |
| 05/10/2006 | EP1015026B1 Il-12 as an adjuvant for bordetella pertussis vaccines |
| 05/10/2006 | EP0946151B1 Ascending-dose dosage form |
| 05/10/2006 | EP0873049B1 Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains |
| 05/10/2006 | EP0765357B9 Antiviral dendrimers |
| 05/10/2006 | CN1771329A The use of PDE4D in the screening for medicaments against atherosclerosis |
| 05/10/2006 | CN1771325A Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs |
| 05/10/2006 | CN1771263A Modified acacia and use thereof |
| 05/10/2006 | CN1771254A Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases |
| 05/10/2006 | CN1771253A Nucleotide lipid ester derivatives |
| 05/10/2006 | CN1771249A Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses. |
| 05/10/2006 | CN1771247A Oxime derivatives and their use as pharmaceutically active agents. |
| 05/10/2006 | CN1771245A Novel crystals of fluorobenzamide derivative |